RATIONALE: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. METHODS: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. RESULTS:Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = -7.8 m, 95% confidence interval, -23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = -0.1 ml/kg/min, 95% confidence interval -2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). CONCLUSIONS:Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life. (clinicaltrials.gov NCT00104637).
RCT Entities:
RATIONALE: Pulmonary hypertension with exercise is common in chronic obstructive pulmonary disease (COPD) and may contribute to exercise limitation in this disease. We aimed to determine the effects of treatment with sildenafil on exercise capacity in patients with COPD and emphysema. METHODS: We performed a randomized, double-blind, placebo-controlled 2-period crossover trial of sildenafil thrice daily in ten adults with COPD and emphysema on CT scan without pulmonary hypertension. We randomized study participants to 4 weeks of sildenafil (or placebo) followed by a 1-week washout and then 4 weeks of placebo (or sildenafil). The 2 primary outcomes were the 6-minute walk distance and oxygen consumption at peak exercise. RESULTS:Sildenafil had no effect on 6-minute walk distance (placebo-corrected difference = -7.8 m, 95% confidence interval, -23.2 to 7.5 m, p = 0.35) or oxygen consumption at peak exercise (placebo-corrected difference = -0.1 ml/kg/min, 95% confidence interval -2.1 to 1.8 ml/kg/min, p = 0.89). Sildenafil increased the alveolar-arterial oxygen gradient (p = 0.02), worsened symptoms (p = 0.04), and decreased quality-of-life (p = 0.03). Adverse events were more frequent while receiving sildenafil (p = 0.005). CONCLUSIONS: Routine sildenafil administration did not have a beneficial effect on exercise capacity in patients with COPD and emphysema without pulmonary hypertension. Sildenafil significantly worsened gas exchange at rest and quality of life. (clinicaltrials.gov NCT00104637).
Authors: Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau Journal: N Engl J Med Date: 2005-11-17 Impact factor: 91.245
Authors: David A Zisman; Marvin Schwarz; Kevin J Anstrom; Harold R Collard; Kevin R Flaherty; Gary W Hunninghake Journal: N Engl J Med Date: 2010-05-18 Impact factor: 91.245
Authors: Denis E O'Donnell; Robert B Banzett; Virginia Carrieri-Kohlman; Richard Casaburi; Paul W Davenport; Simon C Gandevia; Arthur F Gelb; Donald A Mahler; Katherine A Webb Journal: Proc Am Thorac Soc Date: 2007-05
Authors: H Rietema; S Holverda; H J Bogaard; J T Marcus; H J Smit; N Westerhof; P E Postmus; A Boonstra; A Vonk-Noordegraaf Journal: Eur Respir J Date: 2007-12-19 Impact factor: 16.671
Authors: Isabel Blanco; Elena Gimeno; Phillip A Munoz; Sandra Pizarro; Concepción Gistau; Robert Rodriguez-Roisin; Josep Roca; Joan Albert Barberà Journal: Am J Respir Crit Care Med Date: 2009-10-29 Impact factor: 21.405
Authors: Gérald Simonneau; Lewis J Rubin; Nazzareno Galiè; Robyn J Barst; Thomas R Fleming; Adaani E Frost; Peter J Engel; Mordechai R Kramer; Gary Burgess; Lorraine Collings; Nandini Cossons; Olivier Sitbon; David B Badesch Journal: Ann Intern Med Date: 2008-10-21 Impact factor: 25.391
Authors: Jeremy P Wrobel; Catriona A McLean; Bruce R Thompson; Christopher R Stuart-Andrews; Eldho Paul; Gregory I Snell; Trevor J Williams Journal: Pulm Circ Date: 2013-12-11 Impact factor: 3.017
Authors: Raed A Dweik; Sharon Rounds; Serpil C Erzurum; Stephen Archer; Karen Fagan; Paul M Hassoun; Nicholas S Hill; Marc Humbert; Steven M Kawut; Michael Krowka; Evangelos Michelakis; Nicholas W Morrell; Kurt Stenmark; Rubin M Tuder; John Newman Journal: Am J Respir Crit Care Med Date: 2014-02-01 Impact factor: 21.405
Authors: Laura Fossati; Séverine Müller-Mottet; Elisabeth Hasler; Rudolf Speich; Konrad E Bloch; Lars C Huber; Silvia Ulrich Somaini Journal: Lung Date: 2014-10-28 Impact factor: 2.584
Authors: Zoe White; Nadia Milad; Arash Y Tehrani; Jennifer Lamothe; James C Hogg; Mitra Esfandiarei; Michael Seidman; Steven Booth; Tillie-Louise Hackett; Mathieu C Morissette; Pascal Bernatchez Journal: Am J Pathol Date: 2019-05-22 Impact factor: 4.307
Authors: Bradley A Maron; Ronald H Goldstein; Sharon I Rounds; Shelley Shapiro; Matthew Jankowich; Eric Garshick; Marilyn L Moy; David Gagnon; Gaurav Choudhary Journal: Pulm Circ Date: 2013-12 Impact factor: 3.017
Authors: Kari R Gillmeyer; Seppo T Rinne; Mark E Glickman; Kyung Min Lee; Qing Shao; Shirley X Qian; Elizabeth S Klings; Bradley A Maron; Joseph T Hanlon; Donald R Miller; Renda Soylemez Wiener Journal: Circ Cardiovasc Qual Outcomes Date: 2020-05-12